These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 9769621)
61. The analgesic efficacy of subarachnoid morphine in comparison with ultrasound-guided transversus abdominis plane block after cesarean delivery: a randomized controlled trial. Kanazi GE; Aouad MT; Abdallah FW; Khatib MI; Adham AM; Harfoush DW; Siddik-Sayyid SM Anesth Analg; 2010 Aug; 111(2):475-81. PubMed ID: 20488929 [TBL] [Abstract][Full Text] [Related]
62. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T; Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541 [TBL] [Abstract][Full Text] [Related]
63. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. Dudgeon DJ; Bruera E; Gagnon B; Watanabe SM; Allan SJ; Warr DG; MacDonald SM; Savage C; Tu D; Pater JL J Pain Symptom Manage; 2007 Apr; 33(4):365-71. PubMed ID: 17397698 [TBL] [Abstract][Full Text] [Related]
64. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose. Nalamachu SR; Parikh N; Dillaha L; Rauck R J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604 [TBL] [Abstract][Full Text] [Related]
65. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Chou WY; Wang CH; Liu PH; Liu CC; Tseng CC; Jawan B Anesthesiology; 2006 Aug; 105(2):334-7. PubMed ID: 16871067 [TBL] [Abstract][Full Text] [Related]
66. Administration of morphine sulfate extended-release capsules via gastrostomy: dissolution study and case reports. Shaiova L; Mori M; Anderson K; Loewen G; Ghalie R; Homel P; Portenoy R J Palliat Med; 2007 Oct; 10(5):1063-7. PubMed ID: 17985962 [TBL] [Abstract][Full Text] [Related]
67. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Watanabe S; Pereira J; Tarumi Y; Hanson J; Bruera E J Palliat Med; 2008 May; 11(4):570-4. PubMed ID: 18454609 [TBL] [Abstract][Full Text] [Related]
68. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Davis T; Miser AW; Loprinzi CL; Kaur JS; Burnham NL; Dose AM; Ames MM Hosp J; 1993; 9(1):85-90. PubMed ID: 8406404 [TBL] [Abstract][Full Text] [Related]
69. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Katz P; Takyar S; Palmer P; Liedgens H Curr Med Res Opin; 2017 May; 33(5):899-910. PubMed ID: 28318323 [TBL] [Abstract][Full Text] [Related]
70. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Stoker DG; Reber KR; Waltzman LS; Ernst C; Hamilton D; Gawarecki D; Mermelstein F; McNicol E; Wright C; Carr DB Pain Med; 2008; 9(1):3-12. PubMed ID: 18254761 [TBL] [Abstract][Full Text] [Related]
72. Cancer pain management and rectal opioids. Rousseau P South Med J; 1997 Mar; 90(3):365-6. PubMed ID: 9076317 [No Abstract] [Full Text] [Related]
73. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F; Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417 [TBL] [Abstract][Full Text] [Related]
74. Problems with opiates in cancer pain: parenteral opioids. Glare P Support Care Cancer; 1997 Nov; 5(6):445-50. PubMed ID: 9406357 [TBL] [Abstract][Full Text] [Related]
75. Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER). Jamieson L; Harrop E; Johnson M; Liossi C; Mott C; Oulton K; Skene SS; Wong IC; Howard RF Palliat Med; 2021 Jun; 35(6):1118-1125. PubMed ID: 33845654 [TBL] [Abstract][Full Text] [Related]
76. Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration. Nicholson B; Agarwala SS J Opioid Manag; 2011; 7(1):69-79. PubMed ID: 21434586 [TBL] [Abstract][Full Text] [Related]
77. Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review. Gastine S; Morse JD; Leung MT; Wong ICK; Howard RF; Harrop E; Liossi C; Standing JF; Jassal SS; Hain RD; Skene S; Oulton K; Law SL; Quek WT; Anderson BJ BMJ Support Palliat Care; 2024 Jan; 13(e3):e485-e493. PubMed ID: 35184039 [TBL] [Abstract][Full Text] [Related]
78. Carer preferences of route of administration of transmucosal diamorphine and willingness to take part in a randomised controlled trial: an interview study (DIPPER). Jamieson L; Harrop E; Liossi C; Boyce K; Mitchell L; Johnson M; Jani Y; Akinyooye V; Skene SS; Wong ICK; Howard RF; Oulton K BMC Palliat Care; 2022 May; 21(1):78. PubMed ID: 35581660 [TBL] [Abstract][Full Text] [Related]
79. Pharmacological treatment of cancer pain: alternative routes of opioid administration. Ripamonti C; Zecca E; De Conno F Tumori; 1998; 84(3):289-300. PubMed ID: 9678610 [TBL] [Abstract][Full Text] [Related]
80. Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release. Currow DC; Kochovska S; Ferreira D; Johnson M Curr Opin Support Palliat Care; 2020 Sep; 14(3):177-181. PubMed ID: 32740277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]